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Background
Vascular endothelial growth factor (VEGF) is considered
to play an essential role in the pathogenesis of age-
related macular degeneration due to its vascular perme-
ability-inducing and angiogenic properties. Ranibizumab,
a small antibody fragment designed to competitively
bind all VEGF isoforms, passes after intravitreal injec-
tion into all retinal layers reaching the retinal pigment
epithelium-choroid complex. The actions of ranibizu-
mab result in reduced cell proliferation, reduced forma-
tion of new blood vessels, and minimization of vascular
leakage. The aim of this study was to evaluate the pro-
spectively macular function in in patients with neovas-
cular age-related macular degeneration (AMD) patients
undergoing repeated intravitreal injections of Ranibizu-
mab therapy (Lucentis).
Materials and methods
Twenty patients affected by AMD (age range 60-72
years) were enrolled in the study. Inclusion criteria for
this study were: evidence of age-related macular degen-
eration, angiographic evidence of predominantly classic
and occult CNV extending under the center of the
foveal avascular zone, absence of coexisting ocular dis-
ease. Patients enrolled showed baseline visual acuity ran-
ged 1-0.84 logMAR, central microperimetric (Nikon
MP-1) sensitivity 2 to 10 dB. Each patient underwent
weekly assessments, for three months, of visual acuity,
microperimetry and focal electroretinogram (FERG),
performed according to a published technique.
Results
Following the first intravitreal injection, mean visual
acuity (Figure 1), microperimetric sensitivity (Figure 2)
and FERG amplitude (Figure 3) increased steadily from
baseline values over the treatment period, with further
improvements following each intravitreal injection
(P<0.001).
Conclusions
Ranibizumab therapy can improve central macular func-
tion in patients with predominantly classic and occult
CNV.
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Figure 1 Visual acuity (ETDRS)
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Figure 2 Central Microperimetric
Figure 3 FERG amplitude
Scalzo et al. BMC Geriatrics 2010, 10(Suppl 1):A77
http://www.biomedcentral.com/1471-2318/10/S1/A77
Page 2 of 2